- Home
- MAGN vs SVRA Comparison
MAGN vs SVRA Comparison
Compare MAGN & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAGN
- SVRA
- Stock Information
- Founded
- MAGN 1864
- SVRA 2007
- Country
- MAGN United States
- SVRA United States
- Employees
- MAGN N/A
- SVRA N/A
- Industry
- MAGN Paper
- SVRA Biotechnology: Pharmaceutical Preparations
- Sector
- MAGN Basic Materials
- SVRA Health Care
- Exchange
- MAGN Nasdaq
- SVRA Nasdaq
- Market Cap
- MAGN 442.9M
- SVRA 528.3M
- IPO Year
- MAGN N/A
- SVRA N/A
- Fundamental
- Price
- MAGN $13.28
- SVRA $2.39
- Analyst Decision
- MAGN Hold
- SVRA Buy
- Analyst Count
- MAGN 1
- SVRA 5
- Target Price
- MAGN $16.00
- SVRA $5.60
- AVG Volume (30 Days)
- MAGN 942.4K
- SVRA 1.3M
- Earning Date
- MAGN 08-15-2025
- SVRA 08-11-2025
- Dividend Yield
- MAGN N/A
- SVRA N/A
- EPS Growth
- MAGN N/A
- SVRA N/A
- EPS
- MAGN N/A
- SVRA N/A
- Revenue
- MAGN $2,636,000,000.00
- SVRA N/A
- Revenue This Year
- MAGN $47.87
- SVRA N/A
- Revenue Next Year
- MAGN $4.76
- SVRA N/A
- P/E Ratio
- MAGN N/A
- SVRA N/A
- Revenue Growth
- MAGN 15.87
- SVRA N/A
- 52 Week Low
- MAGN $11.43
- SVRA $1.89
- 52 Week High
- MAGN $26.78
- SVRA $5.11
- Technical
- Relative Strength Index (RSI)
- MAGN N/A
- SVRA 53.01
- Support Level
- MAGN N/A
- SVRA $1.98
- Resistance Level
- MAGN N/A
- SVRA $2.50
- Average True Range (ATR)
- MAGN 0.00
- SVRA 0.17
- MACD
- MAGN 0.00
- SVRA 0.05
- Stochastic Oscillator
- MAGN 0.00
- SVRA 78.85
About MAGN Magnera Corporation Common Stock
Magnera Corp formerly Glatfelter Corporation manufactures and sells a variety of paper and fiber products. The company's reportable segments are; Composite Fibers, Spunlace. and Airlaid Materials. The Airlaid Materials segment which is also its key revenue generating segment, is a supplier of cellulose-based airlaid nonwoven materials used to manufacture consumer products for end-user markets. The Airlaid Materials segment produces materials used in feminine hygiene, specialty wipes, tabletop, home care, and other consumables. Geographically, the company derives majority of its revenue from Americas and rest from Europe, Middle East, Africa and Asia Pacific markets.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.